Despite significant reductions in malaria in endemic countries over the past decade, fever is still often presumptively treated as malaria without being properly diagnosed. This leads to overuse of frontline treatment for malaria (ACT) and to the mismanagement of other potentially life-threatening diseases such as pneumonia and diarrhea. The availability of high quality, inexpensive malaria rapid diagnostic tests (mRDTs) has led to improvements in diagnostic testing in the public sector. However, similar gains have not been made in the private sector. This leaves a critical gap in malaria diagnostic testing as private sector outlets such as drug stores and pharmacies are the first point of contact for health services for roughly 40% of the population in endemic countries.
On Tuesday, March 28th at 10AM EST, join PSI for an interactive discussion on how to leverage the power of the private sector to transform the mRDT market in support of universal access to malaria diagnosis.
Drawing on learnings from a three-year project funded by UNITAID to stimulate a private sector market for mRDTs in five sub-Saharan African countries, our panel will provide insights on the key market shortcomings, quality concerns and policy challenges related to the scale-up of mRDTs in the private sector. Panelists will further discuss the importance of public-private engagement in achieving universal diagnostic coverage.
- Nikki Charman, Associate Director Malaria and Child Survival, PSI
- Elizabeth Streat, Senior Public Health Specialist, Malaria Consortium
- Christian Nsanzabana, Scientific Officer, FIND
- Steven Harvey, Assistant Professor, JHSPH
- Nina Martin, Research Associate, JHSPH
- Jane Cunningham, Medical Officer, WHO
- Stephen Poyer, Research Advisor Malaria and Child Survival, PSI
We invite you to take part- click here to register.